From skeletal to cardiovascular disease in 12 steps-the evolution of sclerostin as a major player in CKD-MBD. (Q38367220)

2 September 2017

1 reference

title

From skeletal to cardiovascular disease in 12 steps-the evolution of sclerostin as a major player in CKD-MBD. (English)

1 reference

2 September 2017

cardiovascular disease

1 reference

inferred from title

author name string

Vincent M Brandenburg

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25735207%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Annika Deck

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25735207%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Djalila Mekahli

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25735207%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Ellen Neven

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25735207%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Pieter Evenepoel

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25735207%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

publication date

4 March 2015

1 reference

2 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25735207%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

volume

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25735207%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

page(s)

195-206

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25735207%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25735207%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00467-015-3069-7

4 June 2020

exact match

0 references

cites work

From individual Wnt pathways towards a Wnt signalling network.

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

Wnt/β-catenin signalling: from plasma membrane to nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

Update on Wnt signaling in bone cell biology and bone disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

21 January 2018

Wnt signaling in bone

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

LRP6 mutation in a family with early coronary disease and metabolic risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

The role of wnt signaling in physiological and pathological angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

The Wnt signaling pathway and bone metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

The role of Lrp5/6 in cardiac valve disease: LDL-density-pressure theory

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

Bone: a new endocrine organ at the heart of chronic kidney disease and mineral and bone disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

Is chronic kidney disease-mineral bone disorder (CKD-MBD) really a syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

Osteocyte control of bone formation via sclerostin, a novel BMP antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

Osteoblast and osteocyte: games without frontiers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

Lrp4, a novel receptor for Dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

Analysing the impact of nucleo-cytoplasmic shuttling of β-catenin and its antagonists APC, Axin and GSK3 on Wnt/β-catenin signalling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

High bone density due to a mutation in LDL-receptor-related protein 5

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

High bone mass in mice expressing a mutant LRP5 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

Sclerostin: how human mutations have helped reveal a new target for the treatment of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

Targeted overexpression of Dkk1 in osteoblasts reduces bone mass but does not impair the anabolic response to intermittent PTH treatment in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

Sclerostin alters serum vitamin D metabolite and fibroblast growth factor 23 concentrations and the urinary excretion of calcium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

Sclerostin is positively associated with bone mineral density in men and women and negatively associated with carotid calcified atherosclerotic plaque in men from the African American-Diabetes Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

21 January 2018

The amazing osteocyte

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

WNT signaling in bone homeostasis and disease: from human mutations to treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

Romosozumab in postmenopausal women with low bone mineral density.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

The functions and possible significance of Kremen as the gatekeeper of Wnt signalling in development and pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

Dickkopf1 is required for embryonic head induction and limb morphogenesis in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

The relationship between inhibitors of the Wnt signalling pathway (Dickkopf-1(DKK1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in post-menopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

Renal hypodysplasia associates with a WNT4 variant that causes aberrant canonical WNT signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

Blockade of Wnt/β-catenin signaling by paricalcitol ameliorates proteinuria and kidney injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

CKD-induced wingless/integration1 inhibitors and phosphorus cause the CKD-mineral and bone disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

Antagonism of canonical Wnt/β-catenin signaling: taking RAS blockade to the next level?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

The connections between vascular calcification and bone health

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: a cross-sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

Renal elimination of sclerostin increases with declining kidney function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

Repression of osteocyte Wnt/β-catenin signaling is an early event in the progression of renal osteodystrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

Effects of PTH on osteocyte function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

SOST is a target gene for PTH in bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

Association of circulating sclerostin with bone mineral mass, microstructure, and turnover biochemical markers in healthy elderly men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

Disruption of LRP6 in osteoblasts blunts the bone anabolic activity of PTH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

Osteoporosis and adynamic bone in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

Sclerostin and Dickkopf-1 in renal osteodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

Effects of dietary phosphate on adynamic bone disease in rats with chronic kidney disease--role of sclerostin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

Wnt signaling in cardiovascular physiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

Carotid artery atherosclerosis in hypertensive patients with a functional LDL receptor-related protein 6 gene variant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

Warfarin induces cardiovascular damage in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

Transglutaminase 2-mediated activation of β-catenin signaling has a critical role in warfarin-induced vascular calcification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

Novel insights into osteogenesis and matrix remodelling associated with calcific uraemic arteriolopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

Sclerostin: Another vascular calcification inhibitor?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

Relation of age, gender, and bone mass to circulating sclerostin levels in women and men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

Paediatric reference values for the C-terminal fragment of fibroblast-growth factor-23, sclerostin, bone-specific alkaline phosphatase and isoform 5b of tartrate-resistant acid phosphatase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

Sclerostin levels during growth in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

Sclerostin and DKK1 in Primary Hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

Romosozumab in Postmenopausal Women with Osteopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3069-7

Sclerostin as a potential novel biomarker for aortic valve calcification: an in-vivo and ex-vivo study

21 January 2018

1 reference

12 December 2020

Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass

1 reference

12 December 2020

Serum levels of sclerostin and dickkopf-1: effects of age, gender and fracture status

1 reference

12 December 2020

Wnt signaling and the regulation of bone mass

1 reference

12 December 2020

Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover

1 reference

12 December 2020

Warfarin: to use or not to use in chronic kidney disease patients?

1 reference

12 December 2020

Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients

1 reference

12 December 2020

Sclerostin blood levels before and after kidney transplantation

1 reference

12 December 2020

High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study

1 reference

12 December 2020

Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation

1 reference

12 December 2020